Skip to main
OPT
OPT logo

Opthea (OPT) Stock Forecast & Price Target

Opthea (OPT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Opthea Ltd is advancing its development of OPT-302, a novel biologic therapy aimed at addressing eye diseases associated with vascular growth and leakage, supported by its intellectual property portfolio focusing on key targets such as VEGF-C and VEGF-D. The company is approaching pivotal Phase 3 COAST trial topline results projected for early Q2 CY2025, with strong interim data indicating significant visual acuity improvements, particularly a +5.7 letter gain among high responder subgroups, which enhances the feasibility of broad adoption among retinal specialists. Additionally, feedback from surveyed payers suggests that achieving a minimum of 20% improvement in vision could lead to favorable coverage decisions, reflecting the strong clinical relevance of Opthea's therapeutic developments in the competitive landscape of ophthalmology treatments.

Bears say

Opthea Ltd reported a significant net loss of $131.9 million, translating to $0.11 per share for the first half of fiscal year 2025, indicating financial challenges. The company faces several substantial risks, including the potential failure of its developmental candidate, OPT-302, to achieve projected peak commercial revenues due to factors such as market size and pricing pressures. Additionally, difficulties in securing necessary capital to fund operations and ongoing program development pose further threats to the company's financial health and viability.

Opthea (OPT) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opthea (OPT) Forecast

Analysts have given Opthea (OPT) a Buy based on their latest research and market trends.

According to 8 analysts, Opthea (OPT) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opthea (OPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.